How many rare diseases are there?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 19, 77-78 (2020)

doi: https://doi.org/10.1038/d41573-019-00180-y


NIH grant R24 OD011883 provided funding to M.H., C.M., P.N.R., N.V., J.M., N.H., D.U. and M.P.H. NIH grants U24 CA224370, U24 TR002278, U01 CA239108 and P30 CA118100 provided funding to G.B., C.B., C.M., T.I.O. and P.N.R. The Angela Wright Bennett Foundation and the McCusker Charitable Foundation support Gareth Baynam. OMIM is funded by NIH grant U41 HG006627.


  1. 1.

    Haendel, M. A., Chute, C. G. & Robinson, P. N. Classification, ontology, and precision medicine. N. Engl. J. Med. 379, 1452–1462 (2018).

    PubMed  Article  Google Scholar 

  2. 2.

    Haendel, M. A. et al. A census of disease ontologies. Annu. Rev. Biomed. Data Sci. 1, 305–331 (2018).

    Article  Google Scholar 

  3. 3.

    Oprea, T. I. et al. Unexplored therapeutic opportunities in the human genome. Nat. Rev. Drug Discov. 17, 317-332 (2018).

    PubMed  Article  Google Scholar 

  4. 4.

    Mungall, C. J. et al. k-BOOM: a Bayesian approach to ontology structure inference, with applications in disease ontology construction. bioRxiv 048843; doi: https://doi.org/10.1101/048843 (2019).

  5. 5.

    Tambuyzer, E. et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug Discov. 19, 93–111 (2020).

    PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary Box 1

Competing Interests

M.H., J.M. and T.G. are co-founders of Pryzm Health. T.G. has received funding or consulted for Johnson & Johnson. A.H. owns stock in Blade Therapeutics. T.I.O. has received honoraria or consulted for Abbott, AstraZeneca, Chiron, Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, Roche, Sanofi and Wyeth.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing